Wellington Management Group LLP Has $409,000 Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA)

Wellington Management Group LLP increased its stake in Cabaletta Bio, Inc. (NASDAQ:CABA) by 14.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 180,157 shares of the company’s stock after buying an additional 23,106 shares during the quarter. Wellington Management Group LLP owned approximately 0.37% of Cabaletta Bio worth $409,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CABA. Miller Financial Services LLC bought a new stake in shares of Cabaletta Bio in the 4th quarter valued at about $33,000. Avanza Fonder AB bought a new stake in Cabaletta Bio in the 4th quarter valued at $40,000. Intech Investment Management LLC lifted its holdings in Cabaletta Bio by 42.2% during the 4th quarter. Intech Investment Management LLC now owns 20,203 shares of the company’s stock valued at $46,000 after purchasing an additional 5,999 shares during the last quarter. LPL Financial LLC boosted its position in Cabaletta Bio by 15.6% during the fourth quarter. LPL Financial LLC now owns 42,386 shares of the company’s stock worth $96,000 after purchasing an additional 5,716 shares during the period. Finally, SG Americas Securities LLC increased its holdings in shares of Cabaletta Bio by 23.3% in the fourth quarter. SG Americas Securities LLC now owns 43,259 shares of the company’s stock valued at $98,000 after purchasing an additional 8,161 shares during the last quarter.

Wall Street Analysts Forecast Growth

CABA has been the topic of several research analyst reports. Wells Fargo & Company lowered their price target on shares of Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 1st. Guggenheim reiterated a “buy” rating and issued a $23.00 price target on shares of Cabaletta Bio in a research note on Tuesday, April 1st. UBS Group cut their target price on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Morgan Stanley lowered their target price on shares of Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating for the company in a research note on Tuesday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a report on Tuesday, April 1st. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $21.00.

Cabaletta Bio Trading Down 5.7 %

CABA opened at $1.16 on Tuesday. Cabaletta Bio, Inc. has a 1-year low of $0.99 and a 1-year high of $17.56. The company has a market cap of $58.86 million, a price-to-earnings ratio of -0.54 and a beta of 2.44. The company’s fifty day moving average price is $1.78 and its two-hundred day moving average price is $2.70.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.65). As a group, equities analysts forecast that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current fiscal year.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.